Can Supernus Pharmaceuticals cover its short-term obligations?

Its current ratio is 1.96 — current assets exceed current liabilities.

Where does Supernus Pharmaceuticals's balance sheet data come from?

Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Supernus Pharmaceuticals SUPN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$129.9M+87.4%	$69.33M-7.6%	$75.05M-19.4%	$93.12M-54.2%
Restricted cash	$1.45M—	$0—	$0—	$0—
Accounts receivable, net	$187.8M+32.2%	$142.08M-1.4%	$144.16M-12.9%	$165.5M+11.1%
Inventories	$30.1M—	$0-100%	$77.41M-15.4%	$91.54M+6.5%
Work in process	$29.44M+10.1%	$26.73M-14.4%	$31.21M-1.6%	$31.71M-30.6%
Finished goods	$21.12M+28.4%	$16.44M-45.1%	$29.92M-14.5%	$35.01M+6.3%
Prepaid expenses and other current assets	$65.33M+81.0%	$36.09M+116%	$16.68M+5.7%	$15.78M-41.6%
Total current assets	$644.18M-6.1%	$686.07M+39.1%	$493.11M-32.8%	$734.15M+22.0%
Property and equipment, net	$10.53M-8.8%	$11.55M-14.7%	$13.53M-10.8%	$15.17M-10.5%
Accumulated depreciation	$18.26M+2.4%	$17.84M+15.8%	$15.41M+18.1%	$13.05M-20.7%
Operating lease right-of-use assets	——	——	——	——
Goodwill	$124.88M+6.7%	$117.02M0.0%	$117.02M0.0%	$117.02M-0.4%
Intangible assets, net	$569.46M+9.1%	$521.91M-13.0%	$599.89M-14.6%	$702.46M-10.5%
Deferred tax assets	$38.35M+673%	$4.96M-80.1%	$24.96M-49.9%	$49.81M-41.6%
Other non-current assets	$705K-97.8%	$31.53M-15.9%	$37.51M-5.8%	$39.81M-19.1%
Available-for-sale securities	$180.22M-53.1%	$384.28M+95.6%	$196.44M-57.5%	$462.11M+80.9%
Total assets	$1.45B+6.2%	$1.37B+7.1%	$1.28B-25.0%	$1.7B+0.8%
Accrued expenses	$29.45M—	$0-100%	$4.28M-74.6%	$16.86M-16.2%
Operating lease liabilities, current	$10.61M+54.0%	$6.89M-17.3%	$8.33M+22.7%	$6.79M+4.8%
Total current liabilities	$338.17M+15.7%	$292.4M+0.8%	$290.2M-57.8%	$687.96M+118%
Operating lease liabilities, non-current	$30.37M+10.9%	$27.38M-17.5%	$33.2M-7.8%	$36M-12.8%
Operating Lease Liabilities (Total)	$40.98M+19.6%	$34.27M-17.5%	$41.53M-2.9%	$42.79M-10.4%
Other non-current liabilities	$22.19M+192%	$7.6M+18.3%	$6.42M-26.1%	$8.69M-46.9%
Total liabilities	$31.26M-90.6%	$332.34M-6.7%	$356.16M-56.4%	$816.3M-6.5%
Common stock	130M+232,043%	56K+1.8%	55K+1.9%	54K+1.9%
Additional paid-in capital	$543.83M+13.4%	$479.44M+9.1%	$439.49M+7.7%	$408.12M-6.0%
Retained earnings	$517.88M-6.9%	$556.43M+15.3%	$482.56M+0.3%	$481.25M+26.7%
Accumulated other comprehensive income (loss)	-$44K+76.7%	-$189K+68.1%	-$593K+81.5%	-$3.21M-309%
Total stockholders' equity	$1.06B+2.5%	$1.04B+12.4%	$921.52M+4.0%	$886.2M+8.6%
Total liabilities and stockholders' equity	$1.45B+6.2%	$1.37B+7.1%	$1.28B-25.0%	$1.7B+0.8%
Available-for-Sale Debt Securities	$180.22M-53.1%	$384.28M+114%	$179.82M-51.2%	$368.21M—
Debt securities - current	$180.22M-53.1%	$384.28M+114%	$179.82M-51.2%	$368.21M—
PT Freeport Indonesia (PTFI) mud rush incident insurance settlement receivable	$1.8M-55.0%	$4M—	——	——
Current inventory	$82.39M+51.7%	$54.29M—	——	——
Finished goods	$21.12M+28.4%	$16.44M-45.1%	$29.92M-14.5%	$35.01M+6.3%
Deferred Tax Assets and Other Non-Current Assets	$63.8M+102%	$31.53M-15.9%	$37.51M-5.8%	$39.81M-19.1%
Net Investment in Lease	$26.71M+9.1%	$24.48M-15.6%	$28.99M+0.3%	$28.9M-18.3%
Deferred tax assets	$38.35M—	$0—	——	——
Prepaid pension assets	$705K—	——	——	——
Other intangible assets—net	$569.46M+9.1%	$521.91M-13.0%	$599.89M-14.6%	$702.46M-10.5%
Operating lease right-of-use assets	$26.71M+9.1%	$24.48M-15.6%	$28.99M+0.3%	$28.9M-18.3%
Other non-current assets	$63.8M+102%	$31.53M-15.9%	$37.51M-5.8%	$39.81M-19.1%
Property, plant and equipment at cost	$28.8M-2.0%	$29.39M+1.6%	$28.94M+2.5%	$28.22M-15.5%
Operating Lease Right-of-Use Assets in Other Assets	$26.71M+9.1%	$24.48M-15.6%	$28.99M+0.3%	$28.9M-18.3%
Software and Technology Licenses, Net	$63.8M+102%	$31.53M-15.9%	$37.51M-5.8%	$39.81M-19.1%
Accrued Manufacturing Costs	$29.45M+38.7%	$21.23M+2.4%	$20.72M+22.2%	$16.96M-39.6%
Accrued Royalties (Current)	$2.4M-70.4%	$8.11M+2.4%	$7.92M-34.1%	$12.02M-13.0%
Other Commercial Liabilities	$107.8M+41.2%	$76.35M-4.0%	$79.57M-17.4%	$96.34M-18.1%
Accounts payable and other current liabilities (Note 11)	$107.8M+41.2%	$76.35M-4.0%	$79.57M-17.4%	$96.34M-18.1%
Accrued Liabilities, Current	$107.8M+41.2%	$76.35M-4.0%	$79.57M-17.4%	$96.34M-18.1%
Accrued product returns and rebates	$161.1M-4.5%	$168.71M+9.4%	$154.27M+1.7%	$151.67M+14.3%
Compensation and benefits	$29.45M+38.7%	$21.23M+2.4%	$20.72M+22.2%	$16.96M-39.6%
Other accrued liabilities	$38.22M—	$0-100%	$4.28M-74.6%	$16.86M-16.2%
Professional Service Fees Payable	$16.67M+51.4%	$11.01M-5.6%	$11.67M-30.5%	$16.78M-37.2%
Contingent Consideration Liability (Non-Current)	$206K—	$0-100%	$1.38M-95.9%	$33.85M-5.0%
Total debt	$40.98M+19.6%	$34.27M-17.5%	$41.53M-2.9%	$42.79M-90.0%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	57.5M+3.1%	55.7M+1.9%	54.7M+0.2%	54.6M+1.1%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$57K+1.8%	$56K+1.8%	$55K+1.9%	$54K+1.9%
Number of Exercisable Options	3.6M-12.1%	4.1M+0.7%	4.1M—	——
Number of Vested and Expected to Vest Options	6.3M-5.6%	6.7M+2.1%	6.6M—	——
Share-Based Payment Award Options Outstanding - Number	6.3M-5.6%	6.7M+2.1%	6.6M—	——
Unrealized Gains on Investments	$34K-61.8%	$89K+1,680%	$5K-64.3%	$14K-99.4%
Unrealized Losses on Investments (Before Tax)	$27K-90.7%	$289K-59.9%	$721K-83.0%	$4.24M+1,680%
Weighted Average Exercise Price of Outstanding Options	$32.63+7.2%	$30.44+4.2%	$29.20—	——
Weighted Average Exercise Price of Vested and Expected to Vest Options	$32.63+7.2%	$30.44+4.2%	$29.20—	——
Components	$31.83M+186%	$11.13M—	——	——
Cumulative Cost Basis	$28.8M-2.0%	$29.39M+1.6%	$28.94M+2.5%	$28.22M-88.9%
Fair Value Measurement Disclosure	$31.26M-34.0%	$47.34M-11.4%	$53.45M-2.8%	$54.97M-31.7%
Accrued manufacturing expenses	$25.61M+120%	$11.65M0.0%	$11.65M-23.4%	$15.22M—
Accrued product returns	$37.8M-29.2%	$53.38M-6.8%	$57.29M+27.3%	$45.01M+28.1%
Professional service fees	$16.67M+51.4%	$11.01M-5.6%	$11.67M-30.5%	$16.78M-37.2%
Accrued product rebates	$123.3M+6.9%	$115.33M+18.9%	$96.98M-9.1%	$106.66M+9.3%
Accrued R&D expenses	$7.3M+23.8%	$5.9M-44.0%	$10.53M+40.6%	$7.49M—
Licensing Arrangements	$2.4M-70.4%	$8.11M+2.4%	$7.92M-34.1%	$12.02M-13.0%
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$27K-90.7%	$289K-59.9%	$721K-83.0%	$4.24M+1,680%
Gross Unrealized Gains	$34K-61.8%	$89K+1,680%	$5K-64.3%	$14K-99.4%
Business Combination, Contingent Consideration, Liability	$31.26M-34.0%	$47.34M-11.4%	$53.45M-2.8%	$54.97M-31.7%
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$130M0.0%	$130M0.0%	$130M0.0%	$130M0.0%
Common stock, shares issued (in shares)	$57.46M+3.1%	$55.74M+1.9%	$54.72M+0.2%	$54.63M+1.1%
Common Stock, Shares, Outstanding	$57.46M+3.1%	$55.74M+1.9%	$54.72M+0.9%	$54.25M+1.9%
Investments	$180.22M-53.1%	$384.48M+95.0%	$197.15M-57.7%	$466.33M+84.1%
Estimated Fair Value	$180.22M-53.1%	$384.28M+95.6%	$196.44M-57.5%	$462.11M+80.9%
Inventory, Raw Materials and Purchased Parts, Net of Reserves	$31.83M+186%	$11.13M—	——	——
Other accrued liabilities	$13.09M+87.3%	$6.99M+3.0%	$6.79M-35.6%	$10.53M+85.7%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$32.63+7.2%	$30.44+4.2%	$29.2—	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	$3.64M-12.1%	$4.14M+0.7%	$4.11M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$6.34M-5.6%	$6.72M+2.1%	$6.58M—	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	$6.34M-5.6%	$6.72M+2.1%	$6.58M—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$32.63+7.2%	$30.44+4.2%	$29.2—	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$32.08+8.6%	$29.54+11.1%	$26.58—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Supernus Pharmaceuticals cover its short-term obligations?: Its current ratio is 1.96 — current assets exceed current liabilities.
Where does Supernus Pharmaceuticals's balance sheet data come from?: Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.